Replies to post #143553 on Biotech Values

[BTH]

Are you inferring that the MARQUEE trial for '197 will not meet efficacy when unblinded?

[jq1234]

I don't see why OS HR>0.8 is a big deal in this case. This is NSCLC against Tarceva not placebo. As long as stat significant, I really don't care if HR> or <0.8. Tarceva got approved with HR>0.8 against placebo.

[bladerunner1717]

Hey Clark,

Let's assume, for arguments sake, that the Phase III is a success with an HR <.80. What would you have to conclude about your analysis? In other words, if you turn out to be wrong, how would you critique your own analysis?


Bladerunner